Skip to main content
SpringerLink
Log in

Positive recommendations from the SMC

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. decision dependent upon availability of a Patient Access Scheme

Reference

  • Scottish Medicines Consortium. SMC advice: adapalene 0.1%/benzoyl peroxide 2.5% gel (Epiduo); aflibercept intravitreal (Eylea); azithromycin (Zedbac); dimethyl fumarate (Tecfidera); fluticasone furoate/vilanterol (Relvar Ellipta); lenalidomide (Revlimid); lipegfilgrastim, 6mg, solution for injection (Lonquex); macitentan (Opsumit); rilpivirine 25mg, emtricitabine 200mg, tenofovir disoproxil (as fumarate) 245mg tablet (Eviplera). Internet Document : 7 Apr 2014. Available from: URL: http://www.scottishmedicines.org.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Positive recommendations from the SMC. PharmacoEcon Outcomes News 701, 9 (2014). https://doi.org/10.1007/s40274-014-1210-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1210-7

Search

Navigation